Tamtam Try Tamtam free
Envista Holdings Corporation logo

Envista Holdings Corporation account plan

Global dental solutions provider

At a glance

Envista is a family of more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr, with FY2025 sales of $2,719.5 million.

Envista Holdings Corporation owns more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr, covering implants, orthodontics, digital imaging, restoratives, endodontics and infection prevention. It serves dentists, specialists, dental laboratories and Dental Service Organizations (DSOs) in over 130 countries; about 42% of products went through third-party distributors in 2025. FY2025 sales were $2,719.5 million (+8.3%), operating profit $216.1 million and net income $47.0 million, with approximately 12,000 employees at December 31, 2025. It was formed in 2018 within Danaher and became independent through its 2019 IPO.

Business units

Strategic priorities

Growth, Operations and People
The three company priorities: innovation and commercialization, the Envista Business System for manufacturing performance, and leadership and talent development.
Commercialize the new product pipeline
Recent launches include the S series implant, NOMAD Pro 3 handheld X-ray, DTX Studio Endo Module with AI-assisted canal segmentation and ZenSeal Pro; management says most launches are still below their long-term potential.
Gross margin expansion across the portfolio in 2027
Gross margin has expanded for 3 consecutive quarters; levers are Spark unit cost reduction, diagnostics software and services, and cost of goods sold.
Spark clear aligners and diagnostics share gains
Spark shipped its one millionth case in 2025 and grew high single digits in Q3 2026; Envista says it is the #1 player in North American diagnostics.
Emerging markets and DSOs
Emerging markets were about $586 million of FY2025 sales, and DSOs are named as a fast-growing customer segment to serve at scale.

Latest results

In Q3 2026 (quarter ended October 2, 2026) sales were $691.5 million, up 3.2% with core growth of 2.7%; nine-month sales were $2,127.5 million, up 8.1%. Developed markets grew core 3.5% while emerging markets grew only 0.4% as China declined ahead of volume-based procurement (VBP). Adjusted EBITDA was about $106 million (15.3% margin) and adjusted EPS $0.40. GAAP net income of $508.3 million included a $428.1 million non-cash foreign currency translation gain from dissolving legal entities. 2026 guidance was raised to core growth of 3.75% to 4.25% and adjusted EPS of $1.54 to $1.58.

Investments and deals

Versah acquisition
Versah (Densah burs for osseodensification) was acquired on February 2, 2026 for about $54.4 million; it is one of three bolt-on implant acquisitions over the last year.
Share buybacks
A new $300 million program through December 31, 2029 was authorized on May 5, 2026; $111.2 million was repurchased in the first nine months of 2026.
New Irvine headquarters
A lease for building space in Irvine, California was signed on September 2, 2026, with about $34.2 million of fixed payments, commencing early 2028.
Restructuring
Restructuring charges were $29.3 million in 2025 and $22.1 million in the first nine months of 2026.
R&D and commercial investment
R&D was $114.0 million in 2025 (4.2% of sales); nine-month 2026 R&D was $89.7 million (+9.5%).

Challenges and risks

China volume-based procurement
China is 7%-8% of sales; management expects VBP to cut prices about 50% for orthodontics and 10% to 15% for implants, most likely from the first half of 2027.
Tariffs and trade policy
U.S. tariffs raised costs in 2025; after the IEEPA tariffs were struck down in February 2026, Envista had received $28.2 million of refunds by October 2, 2026.
Soft elective demand
Elective categories such as orthodontics and implants run below historical trends, with U.S. macro uncertainty weighing on patient and clinician confidence.
Distributor concentration
Henry Schein alone was about 12% of 2025 sales, and distributor inventory swings affect results.
Regulation and cyber
The annual report names FDA and EU MDR regulation, cybersecurity and AI use, and indebtedness of approximately $1.5 billion as of February 6, 2026 among the main risks.

What leadership says

“in terms of growth, we think of VBP as a good guy. In terms of margin, we think of it as a bad guy.”

Paul Keel, President and Chief Executive Officer · Envista Q3 2026 earnings call, November 4, 2026

“you should expect continued gross and EBITDA margin expansion from total Envista in 2027.”

Paul Keel, President and Chief Executive Officer · Envista Q3 2026 earnings call, November 4, 2026

“The dental market continued to show its characteristic resilience as patient demand for dental care remained stable despite macro pressures.”

Paul Keel, President and Chief Executive Officer · Envista Q2 2026 earnings call, August 5, 2026

Where a supplier can help

Manufacturing cost reduction
The goal of broader gross margin expansion in 2027, with the bigger opportunity on cost of goods sold and Spark unit cost reduction, suits automation, materials and lean operations suppliers.
Supply chain and trade compliance
Tariff exposure and the plan to offset tariffs through supply chain and pricing actions point to sourcing, trade compliance and logistics services.
Commercial enablement for launches
The priority to commercialize a rich pipeline across more than 3,000 commercial employees fits sales enablement, clinical education and marketing tools, including for DSO accounts.
Software, AI and cybersecurity
DTX Studio software with AI tools and the named cyber and AI-use risks create room for cloud, AI and security vendors.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Envista Holdings Corporation?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Envista Holdings Corporation

What does Envista do?

Envista makes dental products under more than 30 brands, including Nobel Biocare implants, Ormco and Spark orthodontics, DEXIS imaging and Kerr consumables, for dental professionals in over 130 countries.

What is Envista's revenue?

FY2025 sales were $2,719.5 million, up 8.3%, with net income of $47.0 million. Nine-month 2026 sales were $2,127.5 million.

How many employees does Envista have?

Approximately 12,000 at December 31, 2025, about 3,000 of them in the U.S.

Who leads Envista?

Paul Keel is President and Chief Executive Officer; Eric Hammes is CFO.

What is Envista's strategy?

Envista focuses on Growth, Operations and People: commercializing new implant, orthodontic and diagnostics products, expanding margins through the Envista Business System, and growing in emerging markets and with DSOs.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)